10.6084/m9.figshare.12278249.v6
Monique Andersson
Monique
Andersson
eleanor barnes
eleanor
barnes
Tom Beneke
Tom
Beneke
Derrick Crook
Derrick
Crook
Louise Downs
Louise
Downs
David Eyre
David
Eyre
Heli Harvala
Heli
Harvala
William James
William
James
Anita Justice
Anita
Justice
Paul Klenerman
Paul
Klenerman
Sheila F. Lumley
Sheila F.
Lumley
Philippa Matthews
Philippa
Matthews
Anna McNaughton
Anna
McNaughton
Alexander J. Mentzer
Alexander J.
Mentzer
Rutger J. Ploeg
Rutger
J. Ploeg
Jeremy Ratcliff
Jeremy
Ratcliff
David Roberts
David
Roberts
Malcolm G. Semple
Malcolm
G. Semple
Nicole Stoesser
Nicole
Stoesser
Lance Turtle
Lance
Turtle
Maria Zambon
Maria
Zambon
SARS-CoV-2 RNA in blood
figshare
2020
COVID-19
SARS-CoV-2
RNA
Blood
Serum
Prevalence Study
PCR
viraemia
Medical Infection Agents (incl. Prions)
Medical Microbiology not elsewhere classified
Medical Virology
2020-06-24 07:55:32
Dataset
https://figshare.com/articles/dataset/SARS-CoV-2_RNA_in_blood/12278249
<p><a></a>This dataset provides supplementary material for a report of the prevalence of SARS-CoV-2 RNA in blood and blood products.</p><p><br></p><p> </p><p><b>Extended Data File 1: Metadata table providing data for prevalence of SARS-CoV-2 RNA in blood and blood products based on a systematic literature review. </b>Details of 28 citations are presented, and the 22 studies included in quantitative meta-analysis are indicated.</p><p><br></p><p> </p><p><b>Extended Data File 2: qRT-PCR quantification of vRNA from sera and viral culture assays.</b> Calculation of vRNA copy numbers, and qRT-PCR results in figure and table format.</p><p><br></p><p> </p><p><b>Underlying Data File 1: Metadata table providing underlying data for serum samples from adults with confirmed SARS-CoV-2 infection, based on RT-PCR nose/throat swab. </b>Sheet 1: samples obtained through patients recruited into a UK clinical cohort at Oxford University Hospitals NHS Foundation Trust (n=212 samples from 167 unique individuals). Cells highlighted in blue show follow-up samples collected from the same individual at different time points. Cells highlighted in orange show serum PCR positives. Sheet 2: samples obtained from convalescent donors a minimum of 28 days post resolution of symptoms, via NHS Blood and Transplant, NHSBT (n=142 samples from 142 individuals).</p><p><br></p><p><b>RT-PCR Primer sequences: </b>provided in a .xlsx file.</p><p><br></p><p><b> </b></p><p><b>PRISMA checklist: </b>reporting for systematic review and meta-analysis</p><p><br></p><p><b> </b></p><p><b>STROBE checklist: </b>reporting for cohort studies</p><p><br></p><p><b>Fig 4A-D:</b> raw, unedited microscope images of cell cultures. Dates of each image stored in the format YYYYMMDD. </p><p>(A) and (B) are controls:</p><p>(A) Negative control Vero E6 cells in media; </p><p>(B) Cytopathic effect (CPE) in Vero E6 cells spiked with Victoria/01/2020 SARS-CoV-2.</p><p>(C) and (D) are Vero E6 cells inoculated with 1/10 dilution of serum sample from sample VC12 (patient ID UKCOV040), that tested positive for SARS-CoV-2 RNA by RT-PCR:</p><p>(C) Aberrant cellular effects at day 4 in a culture inoculated with VC12 at day 0; </p><p>(D) Normal appearance of cells at day 7 inoculated with 1/10 dilution of the culture supernatant of the VC12-challenged culture, illustrated in (C).</p><p><br></p>